您现在在位置: » 内容
一种治疗套细胞淋巴瘤及慢性淋巴细胞白血病的新药依鲁替尼
作者:许晓辉1,秦雯雯2,刘 璇3 来源:《转化医学电子杂志》 2017-11-29

  【Abstract】 Ibrutinib, as a novel Bruton 'styrosine kinase (BTK) inhibitor, which was firstly acceleratedly approved by USA FDA as a new drug to treat mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia ( CLL). Ibrutinib can block uncontrolled proliferation and spreading of signaling pathways mediated by malignant B cells, which irreversibly inhibits the BTK's activity and cause the inhibition of tumor cell proliferation and survival effectively. Compared with traditional treatment, Ibrutinib shows good advantages and provides a new choice for the treatment of MCL and CLL. In this paper, the basic information, pharmacological effects, synthetic routes and clinical study and application of ibrutinib were introduced.

  【Keywords】 Bruton's tyrosine kinase inhibitor; ibrutinib; mantle cell lymphoma; chronic lymphocytic leukaemia

  【摘 要】 依鲁替尼(ibrutinib)是一种新型 Bruton 酪氨酸激酶 (BTK)抑制剂,是美国食品药品管理局(FDA)首次加速批准上市的新药,主要用来治疗套细胞淋巴瘤(MCL)和慢性淋巴细胞白血病(CLL).依鲁替尼能够阻断介导恶性 B 细胞不可控地增殖和扩散的信号通路,不可逆地抑制 BTK 的活性,有效抑制肿瘤细胞的增殖和存活.与传统的治疗药物相比,依鲁替尼表现出良好的优越性,为 MCL 和 CLL 的治疗提供了一种新的选择. 本研究介绍了依鲁替尼的基本信息、药理作用、合成路线和临床研究及应用.

  【关键词】 Bruton 酪氨酸激酶抑制剂;依鲁替尼;套细胞淋巴瘤;慢性淋巴细胞白血病

  【中图分类号】 R979.1 【文献标识码】 A

  阅读原文:www.ejotm.com/ch/reader/view_abstract.aspx